In Vivo Analysis of Human Immune Responses in Immunodeficient Rats.

Autor:	Ménoret S; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France., Ouisse LH; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France., Tesson L; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France., Remy S; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France., Usal C; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France., Guiffes A; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France., Chenouard V; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France., Royer PJ; Xenothera, Nantes, France., Evanno G; Xenothera, Nantes, France., Vanhove B; Xenothera, Nantes, France., Piaggio E; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France., Anegon I; Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.; Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France.
Jazyk:	angličtina
Zdroj:	Transplantation [Transplantation] 2020 Apr; Vol. 104 (4), pp. 715-723.
DOI:	10.1097/TP.0000000000003047
Abstrakt:	Background: Humanized immune system immunodeficient mice have been extremely useful for the in vivo analyses of immune responses in a variety of models, including organ transplantation and graft versus host disease (GVHD) but they have limitations. Rat models are interesting complementary alternatives presenting advantages over mice, such as their size and their active complement compartment. Immunodeficient rats have been generated but human immune responses have not yet been described. Methods: We generated immunodeficient Rat Rag-/- Gamma chain-/- human signal regulatory protein alpha-positive (RRGS) rats combining Rag1 and Il2rg deficiency with the expression of human signal regulatory protein alpha, a negative regulator of macrophage phagocytosis allowing repression of rat macrophages by human CD47-positive cells. We then immune humanized RRGS animals with human peripheral blood mononuclear cells (hPBMCs) to set up a human acute GVHD model. Treatment of GVHD was done with a new porcine antihuman lymphocyte serum active through complement-dependent cytotoxicity. We also established a tumor xenograft rejection model in these hPBMCs immune system RRGS animals by subcutaneous implantation of a human tumor cell line. Results: RRGS animals receiving hPBMCs showed robust and reproducible reconstitution, mainly by T and B cells. A dose-dependent acute GVHD process was observed with progressive weight loss, tissue damage, and death censoring. Antihuman lymphocyte serum (L1S1) antibody completely prevented acute GVHD. In the human tumor xenograft model, detectable tumors were rejected upon hPBMCs injection. Conclusions: hPBMC can be implanted in RRGS animals and elicit acute GVHD or rejection of human tumor cells and these are useful models to test new immunotherapies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu